By Assoc. Prof. Dr. Mehmet Sorar | Published: 11.02.2025
What Is TMS Parkinson Plus Application?
Transcranial magnetic stimulation (TMS) sends magnetic pulses into the brain through a coil placed on the scalp, and it needs no surgery or sedation. For Parkinson Plus conditions (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies) it is not among the uses cleared by the US FDA, and no standard session programme is known. It remains a subject of research.
How does a TMS session go?
A session follows the general routine that Cleveland Clinic describes for TMS. It is not specific to Parkinson Plus. The usual steps are:
- Metal items are removed and you sit in a reclining chair.
- You wear earplugs or headphones, because the machine clicks loudly.
- The coil is placed on your head and test pulses are used to set the strength.
- Treatment pulses are given. You may feel tapping on the scalp and a twitch in the hand or thumb.
According to Cleveland Clinic, a session takes about 3 to 40 minutes depending on the type. Standard repetitive TMS usually takes 20 to 40 minutes, and theta-burst stimulation, a faster pattern, takes about 3 to 10 minutes. The page adds that some people need maintenance sessions later.
How many sessions are needed, and is there a set programme for these conditions?
For Parkinson Plus conditions there is no set programme. Cleveland Clinic describes a typical schedule of 5 days a week for 4 to 6 weeks, which for depression is often about 30 to 36 sessions, and mentions accelerated programmes with several sessions a day over about 5 days. A leaflet from Oxford Health NHS Foundation Trust also describes an accelerated course (10 days, 3 sessions a day) and a standard one (about 6 weeks, once a day). That service uses TMS only for treatment-resistant depression and anxiety.
Protocols in Parkinson Plus research differ. In the review of multiple system atrophy (MSA) by Zhang and colleagues, the two largest trials gave 10 sessions, aimed at the cerebellum and the left motor cortex. In the study of progressive supranuclear palsy (PSP) by Pilotto and colleagues, each person had one real and one sham session. Zhang and colleagues call brain stimulation a possibly useful rehabilitation strategy but say there is not sufficient confidence in the findings because the studies are few and of low quality. The results are set out on Parkinson Plus and TMS.
Which uses of TMS are cleared?
Cleveland Clinic lists four uses cleared by the US FDA: depression, acute treatment of migraine with aura (with a handheld single-pulse device), obsessive compulsive disorder, and short-term help with quitting smoking. It names Parkinson's disease among conditions under study but not cleared. MSA, PSP, corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB) are not on the list.
Cohen and colleagues, in a timeline of US FDA decisions on TMS devices, date the first clearance to 2008, for adults with depression who had not responded to earlier antidepressants. Later clearances covered obsessive compulsive disorder, migraine, smoking cessation and anxious depression. The timeline lists these as clearances, so "cleared" is the accurate word, not "approved". Cleveland Clinic's page is patient information, not a guideline, and gives no success percentages. It says only that many people with depression or obsessive compulsive disorder notice improvement.
What are the side effects and risks?
TMS has side effects. Cleveland Clinic names headache, scalp discomfort and mild facial twitching as the most common, and says seizure is the most serious side effect and is very rare. It also says TMS does not cause memory loss or thinking problems.
Estimates of seizure risk differ, so one figure would mislead. The Oxford Health leaflet puts it at less than 1 in 30,000 to 50,000 per treatment, and possibly higher with the accelerated course. A 2020 literature review by Stultz and colleagues puts the overall risk of TMS-related seizures below 1%. The leaflet says brain injury, alcohol use, sleep deprivation and some medicines may raise the risk, and that the extra risk ends when the pulses stop. None of these publications gives safety data specific to Parkinson Plus, and the Zhang review does not clearly set out side effects study by study.
Who cannot have TMS?
Cleveland Clinic says metal or electronic implants in the head or neck that cannot be removed, and pacemakers or defibrillators, rule TMS out. The Oxford Health leaflet says people with epilepsy are not usually treated by that service. Examples of barriers are:
- cochlear (inner ear) implants
- aneurysm clips or coils
- implanted brain stimulators
- metal plates and metal fragments
- stents in the neck or brain, metal implants in the eyes or ears, and facial tattoos with metallic ink (Oxford Health leaflet)
- pacemakers and defibrillators
Cleveland Clinic adds that metal elsewhere in the body, such as hip or knee replacements or dental fillings, is generally considered safe.
When should you contact a doctor?
If a seizure happens during or after a session, ask for emergency help. Tell the treating doctor about any epilepsy, past seizures and all medicines before a session, because Cleveland Clinic says seizure risk is higher in these situations and the provider may change medicines or suggest another treatment. Do not stop or change a medicine on your own. A headache that does not settle or is severe should also be reported; the Oxford Health leaflet says headaches usually ease with simple painkillers and become milder as sessions continue.
If a centre suggests TMS for a Parkinson Plus condition, you can ask about the evidence. The group of conditions is described on Overview of Parkinson Plus disease, TMS in general on What is TMS: brain-targeted stimulation, and the steps of ordinary care on Parkinson Plus treatment, the care process.
Sources
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
- Cohen and colleagues, A visual and narrative timeline of US FDA milestones for TMS devices (2022)
- Oxford Health NHS Foundation Trust: rTMS patient information leaflet (2026)
- Stultz and colleagues, Transcranial Magnetic Stimulation (TMS) Safety with Respect to Seizures: A Literature Review (2020)
- Zhang and colleagues, Effects of Non-invasive Brain Stimulation on Multiple System Atrophy: A Systematic Review (2021)
- Pilotto and colleagues, Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study (2021)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi